AKTUALNIE REKRUTUJĄCE BADANIA
Badania prowadzone są w ośrodkach badań klinicznych PRATIA
Chłoniak rozlany z dużych komórek B DLBCL
NAZWA BADANIA
OPIS BADANIA
OŚRODKI PROWADZĄCE
NAZWA BADANIA
OPIS BADANIA
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5)
NAZWA BADANIA
OPIS BADANIA
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients (MINDway)
NAZWA BADANIA
OPIS BADANIA
GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
NAZWA BADANIA
OPIS BADANIA
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
NAZWA BADANIA
OPIS BADANIA
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) (ESCALADE)
NAZWA BADANIA
OPIS BADANIA
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
NAZWA BADANIA
OPIS BADANIA
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) (firmMIND)
NAZWA BADANIA
OPIS BADANIA
A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
NAZWA BADANIA
OPIS BADANIA
Efficacy and Safety of Epcoritamab Monotherapy and in Combination With Lenalidomide as First-line Therapy for Anthracycline-ineligible Diffuse Large B-Cell Lymphoma Patients, an Open-label, Randomized, Multicenter, Global Phase 2 Trial
W tym obszarze czytaj więcej:
Menu
